The authors identified individual randomized controlled trials from previous meta-analyses and additional searches, and then performed meta-analyses on cardiovascular disease outcomes and all-cause mortality. The authors assessed publications from 2012, both before and including the U.S. Preventive Service Task Force review. Their systematic reviews and meta-analyses showed generally moderate-or low-quality evidence for preventive benefits (folic acid for total cardiovascular disease, folic acid and B-vitamins for stroke), no effect (multivitamins, vitamins C, D, b-carotene, Thus, for the general public, the focus has been on meeting requirements through diet, rather than supplements.
Thus, for the general public, the focus has been on meeting requirements through diet, rather than supplements.
Therefore, we reviewed the evidence for supplement use over the last 4 years since the publication of the evidence (6) and guidelines (7) for supplement use of the U.S. Preventive Services Task Force (USPSTF).
METHODS
We conducted a systematic review and meta-analysis of existing systematic reviews and meta-analyses and single randomized controlled trials (RCTs) published in English from January 2012 (1 year before the census, when this field was reviewed comprehensively by the USPSTF) through October 2017 and including the studies reviewed by the USPSTF (6, 7) . We performed a search of published studies in the Cochrane Library, MEDLINE, and PubMed, and used the search terms:
"dietary supplements or supplement*" and "cardiovascular disease or myocardial infarction or stroke or cardiovascular death or mortality or all-cause mortality or death or cancer death or cancer mortality." Specific searches were conducted for individual supplements of the vitamins and minerals in the USPSTF report of 2013 for CVD outcomes and total mortality.
The search was limited to meta-analyses, RCTs, and observational studies (data not reported).
Where $2 meta-analyses with forest plots on the same topic were identified, we identified the unique studies and excluded duplicates, studies that were not relevant, and studies that did not provide data. Full paper review and data extraction were conducted by 2 independent investigators, with all disagreements reconciled through consensus. The extracted data for RCTs included the number of cases and total participants per population for the intervention or exposed group, and also for the control group or nonexposed group. Data were analyzed using Review Manager (RevMan) version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark), and publication bias analysis was conducted using STATA software, version 13.0 (StataCorp, College Station, Texas). To obtain summary estimates, data were pooled using the Mantel-Haenszel method, with data presented only for random effects models. Heterogeneity was assessed using the Cochran Q statistic at p < 0.1 and quantified by the I 2 statistic. An I 2 value $50% indicated substantial heterogeneity (8) .
Publication bias was investigated by visual inspection of funnel plots and quantitative assessment using Begg's and Egger's tests, in which p < 0.05 was considered evidence of small study effects (9) . If <10 trials were available in a meta-analysis, publication bias analysis was not conducted due to insufficient power. The number needed to treat (NNT) and the number needed to harm (NNH) were calculated by the inverse of the absolute risk reduction (ARR) 
INCLUDED RCTs
Attention was drawn to outcomes of meta-analyses that showed significance with moderate-to highquality evidence (with >1 RCT). In this way, we reduced the risk of type 1 errors in the multiple comparison undertaken and avoided the use of corrections, such as the Bonferroni correction, which might have been too conservative (25) .
RESULTS
Assessment of the meta-analyses and single studies of RCTs provided 179 individual studies, 15 of which were published after the USPSTF assessment (6,7). A flow diagram is presented in Figure 1 and also for those that were significant for any of the following: all-cause mortality, CVD mortality, and total CVD risk or related outcomes (e.g., myocardial infarction [MI], stroke), provided that GRADE was more than low-quality evidence, and that >1 RCT was available for assessment (Central Illustration). (A and B) Effects of commonly used vitamins and minerals and (C and D) vitamins with significant effects derived from summary plot estimates of risk ratios expressed as percentages. Popular supplements were without demonstrable effects on cardiovascular disease (CVD) or all-cause mortality. Both folic acid and B-vitamins showed benefits for stroke, whereas antioxidants and niacin showed a marginally significant increase in all-cause mortality. These data highlight the lack of effect of popular supplements on CVD and all-cause mortality but demonstrate potential benefits of folic acid supplementation for stroke. *Slow-release niacin with background statins. NNH ¼ number needed to harm; NNT ¼ number needed to treat.
CENTRAL ILLUSTRATION
Jenkins et al. Summary data showing the risk ratios derived from meta-analyses of RCTs of the 4 most commonly consumed vitamins and mineral supplements (multivitamins, vitamin D, calcium, and vitamin C) on the components of CVD and all-cause mortality. Of note, none of these popular supplements had an effect on CVD or all-cause mortality. CHD ¼ coronary heart disease; CI ¼ confidence interval; MI ¼ myocardial infarction; RR ¼ risk ratio; other abbreviations as in Figure 1 . Antioxidant mixtures had no effect on CVD outcomes, but resulted in an increase in all-cause mortality in the 21 RCT meta-analysis ( Figure 8) Summary data derived from forest plot meta-analyses of RCTs that demonstrate positive effects of folic acid and B-vitamin supplements (of which folic acid is a component) on stroke and marginally significant adverse effects of antioxidants on stroke and niacin and all-cause mortality. Folic acid and stroke prevention (especially in areas without folic acid fortification) is one of the most conclusive findings in this area over the last 6 years. Abbreviations as in Figures 1 and 2 . The following supplements were associated with no significant effect on CVD outcomes and all-cause mortality: vitamins A, B 6 , and E; b-carotene; zinc;
iron; magnesium; selenium; and multivitamins.
DISCUSSION
In general, the data on the popular supplements The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. The results show a RR of 0.80 in favor of folic acid. This 20% reduction in stroke risk was driven by the highly influential Chinese folic acid supplementation study, made in a community without folic acid fortification, but is the major supplement finding of the last 6 years. The number needed to treat (NNT)
for folic acid supplementation and stroke risk is 167. df ¼ degree of freedom; M-H ¼ Manthel-Haenszel; other abbreviations as in Figure 2 . [28] Righetti et al., 2003 [34] Zoungas et al., 2006 -ASFAST [29] Vianna et al., 2007 [35] Huo et al., 2015 -CSPPT [33] Total (95% CI) 10 The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. The results show a RR of 0.83 in favor of folic acid. This 17% reduction in CVD risk was driven by the highly influential Chinese folic acid supplementation study, made in a community without folic acid fortification, but is the major supplement finding of the last 6 years. NNT for folic acid supplementation and CVD risk is 111. Abbreviations as in Figures 1, 2 , and 4.
Jenkins et al. The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. This 10% stroke reduction comes from trials that also include folic acid and from areas with folic acid fortification. These results also support not only B-complex supplementation but also the positive effect of folic acid in stroke prevention. The NNT for vitamin B complex supplementation and stroke risk is 250. *Data for folic acid, B 6 , and B 12 versus placebo from Bønaa et al. (36) . †Data for folic acid, B 6 , and B 12 versus placebo from Ebbing et al. (38) . Abbreviations as in Figures 2 and 4 . The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. The data demonstrate that taking slow-release niacin to lower low-density lipoprotein cholesterol further in those already taking a statin appears not to benefit CVD outcomes but has a marginally adverse effect on all-cause mortality. NNT for niacin without background statin use and all-cause mortality is 100; number needed to harm (NNH) with background statin use and all-cause mortality is 200. *Sang et al. (49); data taken from the meta-analysis in Keene et al.
(94). Abbreviations as in Figures 2 and 4 .
Jenkins et al. The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. Antioxidant mixtures did not appear to benefit CVD outcomes, but many had marginally deleterious effect on all-cause mortality.
Therefore, these supplements cannot be advised for CVD risk reduction. NNH for antioxidants supplementation and all-cause mortality risk for is 250. *Data for vitamin C, vitamin E, b-carotene, selenium, and zinc versus placebo from Girodon et al. (54) . †Data for vitamin C, vitamin E, b-carotene, selenium, and zinc versus placebo from Girodon et al. (55) . Abbreviations as in Figures 1, 2, 4 , and 7. The forest plots show whether the antioxidant mixture contained a specific antioxidant (þ) or not (0), with data on the right or left side of the forest plot depending on expectation was the fact that long-term studies might be required to detect changes in reduced incidence. In addition, the impact of a reduction in these diseases might be too low to be reflected in all-cause mortality.
Furthermore, overall health benefits were expected for multivitamin and multimineral use that also might have been reflected in reduced CVD risk. It has often been noted that a significant proportion of Western diets are not optimal, and it has been reasoned that supplementation could rectify potential deficiencies (89, 90) . If there are no potential adverse effects to supplementation, then it can be argued that some benefits might have been seen, but as yet, they have not.
STRENGTHS AND WEAKNESSES. The strength of this review was that it provided an update on the USPSTF assessment but focused on the components of CVD:
MI, stroke, and their associated mortalities.
The weaknesses included our lack of consideration of data from the fixed-effects model and from the results from cohort studies. RCTs are often of shorter duration, whereas cohorts of longer duration might be required to fully capture chronic disease risk.
Participants in RCTs are often more health-conscious, and therefore, they were not representative of the general population. Supplement differences might also have influenced outcomes. Adherence to and persistence with supplement use were also an issue.
Furthermore, doseÀresponse data were not usually available. However, cohorts might be larger and longer than many RCTs, which would allow the effects of the dose to be assessed. This might require multiple assessments over time and might be confounded by many lifestyle and dietary factors in supplement users that might be difficult to adjust for adequately. Finally, combining different types of antioxidants might be suboptimal, because their mechanisms of action might also be different.
Nevertheless, when studies containing selenium were removed from the meta-analysis, the significance level favoring control increased from p ¼ 0.05 to p ¼ 0.0002 (Figure 10 ), although the risk ratio only increased from 6% to 9% with a number needed to harm reduction of 250 to 127.
We used a random effect model for our metaanalyses. However, the random effects approach might be unsatisfactory when there is heterogeneity among studies because it gives undue weight to Events Total
Control Risk Ratio
The diamond represents the pooled risk estimate. Interstudy heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of p < 0.10 and quantified by the I 2 statistic. Antioxidant mixtures did not appear to benefit CVD outcomes, but many had a marginally deleterious effect on all-cause mortality.
Therefore, these supplements cannot be advised for CVD risk reduction. The NNH for antioxidant supplementation and all-cause mortality risk is 127. Abbreviations as in Although sufficient studies on vitamin D exist, to be confident that there is no all-cause mortality effect, further studies on multivitamins, the most commonly used supplement, may still be useful, because of the marginal benefit seen in our analysis. In the absence of further studies, the current data on supplement use reinforce advice to focus on healthy dietary patterns, with an increased proportion of plant foods in which many of these required vitamins and minerals can be found (5,93).
